ストックスクリーナーアプリを入手
210.60
0.53%
1.10
アフターアワーズ：
210.28
-0.32
-0.15%
前日終値:
$209.50
開ける：
$210.84
24時間の取引高:
4.34M
Relative Volume:
0.79
時価総額：
$372.04B
収益：
$58.33B
当期純損益:
$3.73B
株価収益率:
100.29
EPS:
2.1
ネットキャッシュフロー:
$18.24B
1週間 パフォーマンス:
+1.89%
1か月 パフォーマンス:
+12.55%
6か月 パフォーマンス:
+4.22%
1年 パフォーマンス:
+7.25%
1日の値動き範囲:
$207.12
$211.47
1週間の範囲:
$205.10
$212.45
52週間の値動き範囲:
$163.81
$218.66
Abbvie Inc Stock (ABBV) Company Profile
ABBV を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
ABBV
Abbvie Inc
|
210.60 | 364.92B | 58.33B | 3.73B | 18.24B | 2.10 |
|
LLY
Lilly Eli Co
|
711.68 | 625.77B | 53.26B | 13.80B | -50.20M | 15.30 |
|
JNJ
Johnson Johnson
|
179.29 | 424.47B | 90.62B | 22.66B | 18.18B | 9.35 |
|
NVS
Novartis Ag Adr
|
126.98 | 240.07B | 53.40B | 13.68B | 16.89B | 6.9231 |
|
MRK
Merck Co Inc
|
87.37 | 210.36B | 63.43B | 16.42B | 14.72B | 6.49 |
Abbvie Inc Stock (ABBV) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-08-12 | 再開されました | Piper Sandler | Overweight |
| 2025-08-07 | アップグレード | Daiwa Securities | Neutral → Outperform |
| 2025-05-14 | ダウングレード | Citigroup | Buy → Neutral |
| 2025-04-22 | 開始されました | Cantor Fitzgerald | Overweight |
| 2024-12-10 | 再開されました | BofA Securities | Neutral |
| 2024-12-05 | ダウングレード | Daiwa Securities | Outperform → Neutral |
| 2024-11-22 | アップグレード | Leerink Partners | Market Perform → Outperform |
| 2024-11-15 | 開始されました | Wolfe Research | Outperform |
| 2024-11-04 | アップグレード | Argus | Hold → Buy |
| 2024-10-17 | 開始されました | Bernstein | Mkt Perform |
| 2024-06-05 | アップグレード | HSBC Securities | Hold → Buy |
| 2024-05-17 | 開始されました | Cantor Fitzgerald | Overweight |
| 2024-01-29 | アップグレード | William Blair | Mkt Perform → Outperform |
| 2023-12-18 | ダウングレード | HSBC Securities | Buy → Hold |
| 2023-12-11 | アップグレード | Goldman | Neutral → Buy |
| 2023-11-09 | 開始されました | Deutsche Bank | Hold |
| 2023-10-30 | アップグレード | Barclays | Equal Weight → Overweight |
| 2023-10-20 | 再開されました | UBS | Neutral |
| 2023-09-29 | 開始されました | Raymond James | Outperform |
| 2023-07-25 | 開始されました | William Blair | Mkt Perform |
| 2023-07-14 | 開始されました | HSBC Securities | Buy |
| 2023-04-05 | ダウングレード | Argus | Buy → Hold |
| 2023-03-01 | 開始されました | Guggenheim | Buy |
| 2023-02-22 | ダウングレード | Wolfe Research | Outperform → Peer Perform |
| 2023-02-10 | アップグレード | SVB Securities | Underperform → Market Perform |
| 2022-11-18 | 開始されました | Credit Suisse | Outperform |
| 2022-11-08 | ダウングレード | Societe Generale | Buy → Hold |
| 2022-08-01 | ダウングレード | Atlantic Equities | Overweight → Neutral |
| 2022-05-23 | 開始されました | SVB Leerink | Underperform |
| 2022-05-06 | ダウングレード | Daiwa Securities | Outperform → Neutral |
| 2022-04-06 | 再開されました | Morgan Stanley | Overweight |
| 2022-02-28 | ダウングレード | UBS | Buy → Neutral |
| 2022-02-03 | 繰り返されました | BMO Capital Markets | Outperform |
| 2022-02-03 | 繰り返されました | Barclays | Equal Weight |
| 2022-02-03 | 繰り返されました | BofA Securities | Neutral |
| 2022-02-03 | 繰り返されました | Goldman | Neutral |
| 2022-01-13 | 開始されました | Redburn | Buy |
| 2022-01-12 | 繰り返されました | BMO Capital Markets | Outperform |
| 2021-12-09 | 再開されました | Wells Fargo | Overweight |
| 2021-11-23 | アップグレード | Societe Generale | Hold → Buy |
| 2021-07-27 | 再開されました | Truist | Buy |
| 2021-04-07 | 再開されました | RBC Capital Mkts | Outperform |
| 2020-11-10 | 再開されました | Bernstein | Outperform |
| 2020-09-29 | 開始されました | Berenberg | Hold |
| 2020-06-23 | アップグレード | Atlantic Equities | Neutral → Overweight |
| 2020-06-09 | アップグレード | Wolfe Research | Peer Perform → Outperform |
| 2020-06-02 | アップグレード | Argus | Hold → Buy |
| 2020-05-18 | 再開されました | BofA/Merrill | Neutral |
| 2020-05-12 | アップグレード | JP Morgan | Neutral → Overweight |
| 2020-05-11 | 再開されました | Morgan Stanley | Overweight |
| 2020-04-20 | アップグレード | RBC Capital Mkts | Sector Perform → Outperform |
| 2020-03-23 | ダウングレード | Societe Generale | Buy → Hold |
| 2020-02-27 | 開始されました | Barclays | Equal Weight |
| 2020-02-06 | 開始されました | Mizuho | Buy |
| 2020-01-07 | 開始されました | RBC Capital Mkts | Sector Perform |
| 2019-12-26 | 繰り返されました | Cowen | Outperform |
| 2019-09-26 | アップグレード | Citigroup | Neutral → Buy |
| 2019-08-20 | アップグレード | Piper Jaffray | Neutral → Overweight |
| 2019-06-27 | アップグレード | Wolfe Research | Underperform → Peer Perform |
| 2019-06-26 | アップグレード | SVB Leerink | Mkt Perform → Outperform |
| 2019-05-28 | 開始されました | Goldman | Neutral |
| 2019-04-29 | アップグレード | BMO Capital Markets | Underperform → Market Perform |
すべてを表示
Abbvie Inc (ABBV) 最新ニュース
AbbVie Inc. stock outperforms competitors on strong trading day - MarketWatch
AbbVie Rises 11.5% in a Month: Buy, Hold or Sell the Stock? - The Globe and Mail
Questex’s Fierce Pharma Week Announces Star-Studded Lineup with Jamie-Lynn Sigler, James Van Der Beek, Selma Blair, Kelly Killoran Bensimon and John Duffield to Provide Powerful Stories of Resilience and Healing - GlobeNewswire Inc.
'Break Fee' Classified as Ordinary Deduction: AbbVie, Inc. v. Commissioner - Law.com
Stock Analysis | Abbvie OutlookA Strong Technical Profile and Analyst Optimism - AInvest
Q2 Earnings Highlights: AbbVie (NYSE:ABBV) Vs The Rest Of The Therapeutics Stocks - FinancialContent
AbbVie’s SUNRISE-UC Study: A Real-World Evaluation of Risankizumab in Ulcerative Colitis - TipRanks
AbbVie's Strategic Leap into In Vivo CAR-T with Capstan Acquisition: A Catalyst for Long-Term Value Creation in Immunology Innovation - AInvest
AbbVie closes Capstan Therapeutics acquisition - MSN
AbbVie Completes Acquisition of Capstan Therapeutics - Investing News Network
AbbVie Closes Acquisition of Capstan Therapeutics - MarketScreener
SkinMedica® Unveils Its Newest Hydration Hero - Investing News Network
Abbvie's Stock Falls 0.06% as $1.26B Trading Volume Surges 37.85% to Rank 51st in Daily Activity - AInvest
AbbVie to build API plant in Illinois as it steps up US production - Construction Dive
AbbVie Inc. (ABBV) Trending Stock: Key Takeaways for Investors - AInvest
Here is What to Know Beyond Why AbbVie Inc. (ABBV) is a Trending Stock - Yahoo Finance
If You'd Invested $1,000 in AbbVie Stock 10 Years Ago, Here's How Much You'd Have Today - The Globe and Mail
Glenmark expects ISB 2001 deal with AbbVie to close in September - BusinessLine
Insider Moves: Microsoft, AMD, Boeing, AbbVie, Eli Lilly - TipRanks
AbbVie, Dow, Kratos, Rocket, Applied Materials: Trending by Analysts - TipRanks
AbbVie's Key RICO Claims In Drug Cost Fraud Suit Survive - Law360
AbbVie’s Ubrogepant Study: A Potential Game-Changer for Pediatric Migraine Treatment - TipRanks
Pfizer and AbbVie Advance Pediatric Antibiotic Study: Market Implications - TipRanks
AbbVie’s Promising Phase 2 Study on Metastatic Colorectal Cancer Treatment - TipRanks
AbbVie’s Pediatric Ulcerative Colitis Study: A Potential Game-Changer - TipRanks
AbbVie’s Promising Phase 3 Study on Etentamig for Multiple Myeloma - TipRanks
AbbVie Stock (ABBV) Opinions on Recent Price Breakout and Expansion Plans - Quiver Quantitative
Stephen Hahn steps down as CEO of Flagship biotech; A new era at AbbVie partner Gubra - Endpoints News
ABBV LAWSUIT ALERT: Levi & Korsinsky Notifies AbbVie Inc. Investors of a Class Action Lawsuit and Upcoming Deadline - Newsfile
AbbVie to invest $195M to build plant in Illinois - MSN
AbbVie’s Promising Phase 3 Study on Upadacitinib for Takayasu Arteritis - TipRanks
Stocks Generating Improved Relative Strength: AbbVie - MSN
AbbVie’s Promising Gene Therapy for Wet AMD: A Game Changer? - TipRanks
AbbVie’s ABBV-453 Study: A New Hope for Multiple Myeloma Treatment - TipRanks
AbbVie’s Promising Phase 3 Study on Upadacitinib for Vitiligo - TipRanks
Glenmark Pharma's Strategic Global Expansion and Revenue Catalysts: A Deep Dive into Long-Term Growth and Immediate Opportunities - AInvest
Will AbbVie Inc. benefit from macro trendsWeekly Trend Report & Weekly Setup with ROI Potential - Newser
Abbvie Surges 1.42% on $195M Expansion as $0.72B Trading Volume Ranks 165th - AInvest
AbbVie to Invest $195 Million in US API Manufacturing - PharmTech
AbbVie to invest $195 million in US drug ingredient manufacturing - The American Bazaar
AbbVie (ABBV) Invests US$195 Million To Expand U.S. Pharmaceutical Production - Yahoo Finance
AbbVie shares rise 1.06% intraday after announcing a $195 million investment in Illinois manufacturing facility. - AInvest
AbbVie’s Innovative Approach to NSCLC Treatment: A New Clinical Study Update - The Globe and Mail
Cantor Fitzgerald raises Abbvie stock price target to $215 on strong Skyrizi performance - Investing.com Canada
AbbVie to invest $195m in new API production facility in US - World Pharmaceutical Frontiers
AbbVie Injects $195 Million Into US Active Pharmaceutical Ingredient Manufacturing - Powder & Bulk Solids
AbbVie investing $195 million in API manufacturing facility - The Pharma Letter
AbbVie expands North Chicago API production with $195m investment - Pharmaceutical Technology
AbbVie invests $195M to expand API manufacturing capabilities - Serrari Group
5 Insightful Analyst Questions From AbbVie’s Q2 Earnings Call - Yahoo Finance
$195M AbbVie Expansion Boosts Illinois Pharma Industry - Business Facilities
Abbvie Inc (ABBV) 財務データ
収益
当期純利益
現金流量
EPS
0.20%
0.69%
大文字化:
|
ボリューム (24 時間):